Interferon/long-term lamivudine combination therapy in anti-HBe positive chronic hepatitis B patients
| Autor: | Kalliopi Patsiaoura, Eleni Orfanou-Koumerkeridou, Konstantinos Tziomalos, Aikaterini Balaska, Olga Giouleme, Nikolaos Eugenidis, Nikolaos Nikolaidis, Panagiotis Doukelis, Themistoklis Vassiliadis, Nikolaos Grammatikos, Adamos Saveriadis, Anastasios D Voutsas |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty HBsAg Hepatitis B virus Time Factors Combination therapy medicine.disease_cause Gastroenterology Antiviral Agents Drug Administration Schedule Hepatitis B Chronic Interferon Recurrence Internal medicine Drug Resistance Viral medicine Humans Hepatitis B e Antigens Hepatitis B Antibodies Aged Hepatology Reverse-transcriptase inhibitor business.industry Lamivudine Breakthrough infection Middle Aged Discontinuation Immunology Mutation Reverse Transcriptase Inhibitors Drug Therapy Combination Female Interferons business medicine.drug |
| Zdroj: | Journal of gastroenterology and hepatology. 20(11) |
| ISSN: | 0815-9319 |
| Popis: | Background: Monotherapy with a single antiviral agent is insufficient in controlling hepatitis B virus infection in the majority of patients with anti-HBe positive chronic hepatitis B. Interferon/long-term lamivudine combination therapy was evaluated to determine if this strategy would improve treatment efficacy and reduce the emergence of lamivudine resistance. Methods: In total, 36 consecutive anti-HBe positive patients were treated with interferon (3 MU subcutaneously three times weekly) and lamivudine (100 mg orally once a day) for 12 months. After completion of the combined treatment, all patients continued to receive lamivudine monotherapy indefinitely. Results: Overall, 35 patients (97%) showed virological response at 12 months. Four patients (11%) cleared HBsAg and developed anti-HBs. During the follow-up time, after the discontinuation of interferon, of 30 ± 12 months (range: 7–57 months), 13 patients (36%) exhibited breakthrough infection. The cumulative rates of breakthrough infection at the end of 1, 2, 3 and 4 years of treatment were 0%, 14%, 32%, and 59%, respectively. Conclusions: Combination therapy appears to be effective and may also delay the selection of lamivudine-resistant variants. However, controlled trials are definitely warranted to clarify the potential benefits of combination antiviral treatment over monotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text